What Zoetis's latest 10-Q says: 7 signals
Zoetis filed its latest 10-Q with the SEC on Aug 6, 2026. It discusses capex increase, debt refinancing and inflation impact.
Public (ZTS)Pharmaceutical Manufacturing10,000+ employeeszoetis.comLinkedIn
- Filed
- Aug 6, 2026
- Filings
- 2
- Signals
- 13
10-Q · latest 9
What Zoetis's 10-Q filings say
- SEC EDGAR
10-Q
Filed · 7 signals
Zoetis launching multi-year, cloud-based ERP system replacement initiative.
The company is undergoing a multi-year implementation to replace its existing ERP with a new cloud-based system.
ERPcloud
Zoetis raises $1.85B in new debt, leaving substantial funds for general corporate purposes.
After issuing $1.85B in senior notes and redeeming $1.35B of older notes, Zoetis has approximately $500M in new capital available for general corporate purposes.
$1.9B
Aggregate principal amount of new senior notes issued.
Deutsche Bank Trust Company AmericasJPMorgan Chase Bank, N.A.
Company highlights significant competitive pressure from generic drug alternatives.
Zoetis explicitly identifies competition from generic products as a material risk, which typically leads to price erosion and margin compression.
generic alternativesbranded and generic competitors
Zoetis flags risk of manufacturing problems and capacity imbalances leading to higher costs.
The company identifies potential for manufacturing issues to cause inventory shortages and unanticipated costs, indicating a pain point around production efficiency and supply chain resilience.
Zoetis identifies inflation and economic weakness in China as key business risks.
Management lists inflation and a decline in global economic conditions as factors that could materially impact future results, suggesting pressure on costs and margins.
- SEC EDGAR
10-Q
Filed · 6 signals
Zoetis is undergoing a multi-year, cloud-based ERP system replacement.
The company is in a phased, multi-year process of replacing its existing ERP with a new, fully cloud-based system.
ERPcloudJPMorgan Chase Bank, N.A.Deutsche Bank Trust Company Americas
Zoetis flags risk to internal controls from ongoing ERP system upgrade.
The company's multi-year ERP replacement is acknowledged as a potential material risk to internal controls over financial reporting, creating a need for GRC, process automation, and audit/compliance solutions to manage the transition.
ERPcloud
Zoetis raised $1.85B in senior notes, retaining funds for general corporate purposes.
The company issued $1.85 billion in new debt in August 2025, using the proceeds to refinance existing notes and retaining the remainder for general corporate use.
$1.9B
Total aggregate principal of senior notes issued
Deutsche Bank Trust Company Americas
Zoetis completed a $2.0B convertible senior notes offering in Dec 2025.
The company raised $2.0 billion through a private offering of convertible senior notes, using proceeds for complex financial transactions including share repurchases and capped calls, indicating a sophisticated and active treasury function with significant capital.
$2B
Aggregate principal of convertible senior notes offering
JPMorgan Chase Bank, N.A.
Showing 9 of 13 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Zoetis earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Facing aggressive competition and share loss in dermatology marketExecutives acknowledged losing market share in the key dermatology franchise due to aggressive promotional activity, discounting, and sampling from competitors with new product launches. This pressure makes them receptive to solutions that can defend market share, such as competitive intelligence platforms, sales enablement, and marketing automation. | |
| Investing in new biologics facility and manufacturing expansionThe company is actively investing in manufacturing excellence, including a new Advanced Biologics facility in Atlanta and expanded monoclonal antibody production. This signals significant CapEx budget for construction, manufacturing equipment, automation, and supply chain solutions. | |
| Planning two major new drug launches for H1 2026.Zoetis has secured approvals for Lenivia and Portela, two new OA pain drugs, with launches planned for the first half of 2026. This will drive significant spending on marketing, sales force training, commercial launch support, and supply chain logistics. | |
| Funding new Phase IV research to combat negative product perceptions.To counter a 15% sales decline in its Librela drug caused by social media 'misperceptions', the company is investing in third-party Phase IV studies starting in Q4. This represents a dedicated budget to solve a critical business problem, creating opportunities for clinical research organizations (CROs), data analysis, and brand management vendors. | |
| Focusing on alternative channels to drive compliance and convenienceTo combat softness in vet clinics, the company is focusing on retail and home delivery channels, which grew 21% in the quarter. This strategic shift to meet customer demand for convenience opens opportunities for vendors in e-commerce, DTC marketing, and logistics. | |
| Expanding product portfolio in key Latin American markets.The company is actively expanding its geographic footprint, citing recent approvals for its Simparica Trio franchise in Brazil and Apoquel Chewable in Chile. This creates needs for localized marketing, distribution partnerships, and regulatory support in those regions. |
Signal API · MCP
Track Zoetis with the Signal API
One POST /v1/companies/enrich call with zoetis.com returns Zoetis 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"zoetis.com","signal_types":["sec-10q"],"limit":20}'Same industry
10-Q at related companies
Questions about Zoetis 10-Q
When did Zoetis file its latest 10-Q?
What did Zoetis disclose in its latest 10-Q?
What did Zoetis say on its recent earnings calls?
Where can I read Zoetis's 10-Q filing?
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .